Hamlet BioPharma Nominates Elisabeth Parker to Board of Directors
Hamlet BioPharma announced the nomination of Dr. Elisabeth Parker to its Board of Directors. Dr. Parker brings over 20 years of experience in business development and international networks within the pharmaceutical industry.
Lund, Sweden – Hamlet BioPharma, a pharmaceutical company advancing clinical trials for infectious diseases and cancer, has nominated Dr. Elisabeth Parker to its Board of Directors. This appointment is expected to strengthen the company's growth through enhanced business development and international pharmaceutical industry connections.
Dr. Parker brings over two decades of professional experience in research and development, partnership building, and commercialization of translational research within the healthcare sector. She currently serves as a Senior Investment Advisor for Healthcare and Life Sciences at Business Sweden in London.
Her previous roles include Director of Business Development at Macrophage Pharma Ltd. and Business Development Executive at Cancer Research Technology Ltd., the commercialization arm of Cancer Research UK. Dr. Parker has also served as a Non-Executive Director for Arquer Ltd, a cancer diagnostic company, and Azeria Therapeutics Ltd, a cancer therapeutics firm.
"Dr. Parker's experience and network in the pharmaceutical and life sciences sectors will be an invaluable addition to our Board," said Catharina Svanborg, Chairman of the board of Hamlet BioPharma. "Her insights and expertise in commercialization and business development will be essential to develop our rich pipeline of molecules into useful treatments."